Susanna Gatti High - Nov 2, 2023 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role: Chief Operating Officer
Signature: /s/ Richard Scalzo, Attorney-in-Fact
Stock symbol: DYN
Transactions as of: Nov 2, 2023
Transactions value $: -$73,549
Form type: 4
Date filed: 11/2/2023, 05:16 PM
Previous filing: Sep 20, 2023
Next filing: Nov 16, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DYN	Common Stock	Sale	-$73.5K	-9.94K	-9.51%	$7.40	94.6K	Nov 2, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 10, 2023.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $7.12 to $7.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.

Content

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 10, 2023.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $7.12 to $7.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.